Latest Development Programs News

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Paradigm will return the US$2 million drawn from Obsidian earlier this month and cancel the associated convertible notes, without an additional payment. The decision comes as the biotechnology company reviews interim data from its pivotal knee osteoarthritis trial and prepares a separate update on funding and operations.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

Finbar Group (ASX:FRI) delivered its strongest annual profit since FY2015, with net profit rising 40.9% to $20.3 million despite lower revenue. Record pre-sales, reduced debt and a $1.95 billion development pipeline give the Perth apartment developer a substantial FY27 workload.

Delta Lithium reported a $13.2 million FY2026 profit after separating its gold assets into Ballard Mining, while advancing lithium projects at Mt Ida and Yinnetharra. The result was supported heavily by demerger-related accounting gains, leaving the next test firmly operational: whether the projects can move towards production.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

Innovaero Technologies is seeking A$40 million through a proposed ASX listing to advance its OWL loitering munition program and expand manufacturing capacity. The replacement prospectus also makes clear that the company remains loss-making and heavily dependent on the Department of Defence converting development work into production orders.

Chariot Resources has secured A$1.1 million from institutional and sophisticated investors to advance its proposed Nigerian lithium acquisition, exploration and partner-funded development program. The raising also brings potential option dilution and only partially addresses the company’s secured debt.

Ceretas has completed the third milestone of its government-backed CUREator+ program, unlocking a final $692,578 non-dilutive funding tranche. The work delivered functional prototypes of proprietary neuronavigation software and a lift assist device intended to simplify operation of its next-generation Alzheimer’s ultrasound system.

Prescient Therapeutics has extended its Share Purchase Plan by three days after shareholders reported delays receiving application documents. The revised timetable places the offer’s results announcement just ahead of a planned briefing on the company’s PTX-100 development program.

Red Sky Energy has started drilling Yarrow 5 in South Australia, the second well in a three-well development program operated by Santos. The well is expected to reach 2,775 metres by 14 September, with a further re-entry planned before first gas from Yarrow North 1 is targeted for early 2027.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.